Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Satoshi Hirano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2612-9913; OpenAlex author ID A5090915905, A5130108822. Sources: OpenAlex.

Their work

Papers
70 (first author 3, last author 26)
Trials
0
Grants
0
Labs led
1
Collaborators
254
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 5 papers · 2019: 6 papers · 2020: 8 papers · 2021: 3 papers · 2022: 9 papers · 2023: 3 papers · 2024: 6 papers · 2025: 7 papers · 2026: 9 papers

Papers 50 of 70

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Distance From the Root of the Splenic Artery to the Tumor as a Predictor of Para-Aortic Lymph Node Metastasis in Left-Sided Pancreatic Cancer. Last author DOI 10.1002/jhbp.70074↗
  4. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  5. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  6. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  7. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  8. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  9. Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
  10. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  11. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  12. Hydrogel PCDME creates pancreatic cancer stem cells in OXPHOS metabolic state with TXNIP elevation. Co-author DOI 10.1016/j.bbrc.2025.151416↗
  13. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  14. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  15. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  16. Seven-year survival with no recurrence after conversion surgery for pancreatic ductal adenocarcinoma with peritoneal metastasis treated with intraperitoneal an… Last author DOI 10.3892/mco.2025.2908↗
  17. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  18. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model. Last author DOI 10.1016/j.biopha.2023.116052↗
  19. A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study. Co-author DOI 10.1016/j.eclinm.2024.102936↗
  20. Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. Last author DOI 10.1038/s41417-024-00810-7↗
  21. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16100↗
  22. Prognostic value of combined psoas muscle mass and controlling nutritional status in patients with pancreatic ductal adenocarcinoma: a retrospective cohort stu… Last author DOI 10.1186/s12893-024-02395-2↗
  23. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  24. Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3762↗
  25. Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells. Last author DOI 10.3390/cancers15030601↗
  26. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  27. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-14094-0↗
  28. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  29. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  30. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  31. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Last author DOI 10.1245/s10434-022-11630-0↗
  32. ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-022-11735-6↗
  33. ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines Co-author DOI 10.21203/rs.3.rs-1897319/v1↗
  34. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms231911521↗
  35. A novel laparoscopic near-infrared fluorescence spectrum system for photodynamic diagnosis of peritoneal dissemination in pancreatic cancer. Last author DOI 10.1016/j.pdpdt.2020.102157↗
  36. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cance… Co-author DOI 10.1186/s12964-021-00733-y↗
  37. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  38. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  39. Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. Co-author DOI 10.1016/j.bbrc.2020.01.105↗
  40. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  41. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. Last author DOI 10.1097/mpa.0000000000001665↗
  42. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  43. Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. Last author DOI 10.1158/1535-7163.mct-19-0491↗
  44. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer. Co-author DOI 10.1186/s12964-020-00608-8↗
  45. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. Last author DOI 10.5009/gnl18573↗
  46. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… Co-author DOI 10.1002/ags3.12272↗
  47. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? Last author DOI 10.1007/s11605-018-3972-x↗
  48. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Last author DOI 10.1016/j.ijrobp.2019.07.004↗
  49. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Co-author DOI 10.1073/pnas.1901765116↗
  50. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cas.14023↗

Closest collaborators

The 25 strongest of 254 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Nakamura · 28 shared papers, 2013–2024 · strength 2.68
  2. Sohei Satoi · 17 shared papers, 2013–2026 · strength 2.67
  3. Takahiro Tsuchikawa · 22 shared papers, 2011–2024 · strength 1.84
  4. Michiaki Unno · 9 shared papers, 2022–2026 · strength 1.73
  5. Toshimichi Asano · 14 shared papers, 2017–2026 · strength 1.59
  6. Toshiaki Shichinohe · 18 shared papers, 2011–2024 · strength 1.36
  7. Kenichiro Uemura · 7 shared papers, 2022–2026 · strength 1.27
  8. Tsutomu Fujii · 9 shared papers, 2020–2026 · strength 1.25
  9. Teiichi Sugiura · 6 shared papers, 2023–2026 · strength 1.17
  10. Daisuke Hashimoto · 7 shared papers, 2021–2026 · strength 1.14
  11. Masamichi Mizuma · 6 shared papers, 2025–2026 · strength 1.13
  12. Itaru Endo · 6 shared papers, 2022–2026 · strength 1.06
  13. Masayuki Sho · 6 shared papers, 2013–2026 · strength 0.99
  14. Masayuki Ohtsuka · 5 shared papers, 2025–2026 · strength 0.95
  15. Hiroki Yamaue · 7 shared papers, 2013–2026 · strength 0.95
  16. Goro Honda · 5 shared papers, 2022–2026 · strength 0.91
  17. So Yamaki · 6 shared papers, 2020–2026 · strength 0.91
  18. Fuyuhiko Motoi · 6 shared papers, 2020–2026 · strength 0.91
  19. Yoshitsugu Nakanishi · 10 shared papers, 2017–2022 · strength 0.87
  20. Katsuhisa Ohgi · 4 shared papers, 2025–2026 · strength 0.79
  21. Kenjiro Okada · 4 shared papers, 2025–2026 · strength 0.78
  22. Suguru Yamada · 5 shared papers, 2020–2026 · strength 0.77
  23. Masafumi Imamura · 5 shared papers, 2019–2026 · strength 0.75
  24. Tomohisa Yamamoto · 6 shared papers, 2020–2025 · strength 0.69
  25. Shintaro Takeuchi · 7 shared papers, 2015–2026 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.